| Sotrovimab (sotrovimab) |
GlaxoSmithKline Inc |
Treatment |
Authorized By Interim Order |
|
No |
36 |
| Casirivimab and imdevimab (casirivimab / imdevimab) |
Hoffmann-La Roche Limited |
Treatment |
Authorized By Interim Order |
|
No |
34 |
| Janssen COVID-19 Vaccine (Ad26.COV2.S [recombinant]) |
Janssen Inc |
Vaccine |
Authorized By Interim Order |
|
No |
27 |
| Vaxzevria (ChAdOx1-S [recombinant]) previously Astrazeneca Covid-19 Vaccine |
AstraZeneca Canada Inc |
Vaccine |
Authorized By Interim Order |
|
No |
28 |
| COVISHIELD (ChAdOx1-S [recombinant]) Expired September 16 2021 |
Verity Pharmaceuticals Inc/Serum Institute of India (in partnership with AstraZeneca Canada Inc) |
Vaccine |
Authorized By Interim Order |
|
No |
29 |
| SPIKEVAX (elasomeran) previously COVID-19 Vaccine Moderna |
ModernaTX, Inc. |
Vaccine |
Authorized By Interim Order |
|
No |
15 |
| Comirnaty (tozinameran) previously Pfizer-BioNTech COVID-19 Vaccine |
BioNTech Manufacturing GmbH |
Vaccine |
Authorized By Interim Order |
|
No |
16 |
| Bamlanivimab (bamlanivimab) |
Eli Lilly Canada Inc |
Treatment |
Authorized By Interim Order |
|
No |
8 |
| Veklury (remdesivir) |
Gilead Sciences Canada Inc |
Treatment |
Authorized |
|
No |
9 |
| Covaxin (whole virion inactivated corona virus) |
Vaccigen Ltd |
Vaccine |
Under review |
Under review |
No |
77 |
| Nitric oxide (nitric oxide) |
Sanotize Research & Development Corp. |
Treatment |
Under review |
Under review |
Yes |
76 |
| COVID-19 Vaccine Moderna – Application for Pediatric Use (ages 12-17) (mRNA-1273 SARS-CoV-2) |
ModernaTX, Inc. |
Vaccine |
Under review |
Under review |
No |
55 |
| Regdanvimab (regdanvimab) |
Celltrion HealthCare Co Ltd |
Treatment |
Under review |
Under review |
No |
53 |
| Olumiant (baricitinib) |
Eli Lilly Canada Inc |
Treatment |
Under review |
Under review |
Yes |
39 |
| Coronavirus-like Particle (CoVLP) COVID-19 Vaccine (coronavirus-like particle [CoVLP]) |
Medicago Inc |
Vaccine |
Under review |
Under review |
No |
38 |
| Leronlimab (leronlimab) |
CytoDyn, Inc |
Treatment |
Under review |
Under review |
No |
35 |
| Bamlanivimab and etesevimab (LY-CoV555 / LY-CoV016) |
Eli Lilly Canada Inc |
Treatment |
Under review |
Under review |
No |
32 |
| Novavax COVID-19 Vaccine (NVX-CoV2373) |
Novavax Inc |
Vaccine |
Under review |
Under review |
No |
31 |
| Favipiravir (favipiravir) |
Dr Reddys Laboratories Ltd |
Treatment |
Under review |
Under review |
|
17 |
